{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:58:39Z","timestamp":1785301119282,"version":"3.55.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>There is a paucity of literature investigating the use of liposomal bupivacaine (LB) in a dermatologic surgery setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To identify the treatment characteristics and adverse events, including Local Anesthetic System Toxicity (LAST), in patients receiving perioperative LB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS<\/jats:title>\n                    <jats:p>A retrospective chart review was performed at a single institution using an institutional database and key words \u201cExparel\u201d or \u201cliposomal bupivacaine.\u201d Patients \u226518 years old who received perioperative LB to the surgical site and surrounding skin were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      A total of 140 LB administrations and 129 patients were included. Liposomal bupivacaine was used most often in the setting of excisions (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 88, 62.9%) and Mohs micrographic surgery (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 49, 35%), with hidradenitis suppurativa (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 77, 55%) and cutaneous neoplasms (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 56, 40%) the most frequent diagnoses. The median postoperative area and length were 23.6 cm\n                      <jats:sup>2<\/jats:sup>\n                      and 15.4 cm, respectively. The median LB dosage was 20 mL (range 1.5\u201320). There were no adverse events in 134 out of 136 patients of LB administration (98.5%). There were 2 reports (1.5%) of nausea on POD1 while these patients were taking opioids.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Liposomal bupivacaine should be considered for postoperative analgesia in patients undergoing dermatologic surgery because it is well tolerated and efficacious. The authors observed no cases of LAST.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/dss.0000000000005031","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T14:00:46Z","timestamp":1769608846000},"page":"743-747","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The Safety of Perioperative Liposomal Bupivacaine Injections in Dermatologic Surgery Patients"],"prefix":"10.1097","volume":"52","author":[{"given":"Melissa M.","family":"Rames","sequence":"first","affiliation":[{"name":"Department of Dermatology, Mayo Clinic, Rochester, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge A.","family":"Rios-Duarte","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Mayo Clinic, Rochester, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahid Y.","family":"Vidal","sequence":"additional","affiliation":[{"name":"Division of Dermatologic Surgery, Department of Dermatology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"R1-20260729","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/dsu.12166","article-title":"Assessment of postoperative pain after Mohs micrographic surgery","volume":"39","author":"Limthongkul","year":"2013","journal-title":"Dermatol Surg"},{"key":"R2-20260729","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1524-4725.2011.02022.x","article-title":"A randomized controlled trial comparing acetaminophen, acetaminophen and ibuprofen, and acetaminophen and codeine for postoperative pain relief after Mohs surgery and cutaneous reconstruction","volume":"37","author":"Sniezek","year":"2011","journal-title":"Dermatol Surg"},{"key":"R3-20260729","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jaad.2009.10.049","article-title":"An analysis of pain and analgesia after Mohs micrographic surgery","volume":"63","author":"Firoz","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"R4-20260729","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/DSS.0000000000002116","article-title":"Patient concerns in the immediate postoperative period after Mohs micrographic surgery","volume":"46","author":"Giordano","year":"2020","journal-title":"Dermatol Surg"},{"key":"R5-20260729","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/bcpt.13998","article-title":"Dose safety and pharmacodynamics of subcutaneous bupivacaine in a novel extended-release microparticle formulation: a phase 1, dose-ascending study in male volunteers","volume":"134","author":"Jensen","year":"2024","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R6-20260729","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1080\/14740338.2017.1335304","article-title":"Local anesthetics systemic toxicity association with exparel (bupivacaine liposome)- a pharmacovigilance evaluation","volume":"17","author":"Aggarwal","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"R7-20260729","doi-asserted-by":"crossref","first-page":"20","DOI":"10.29245\/2768-5365\/2023\/2.1144","article-title":"Three cases of local anesthetic systemic toxicity following regional infiltration analgesia: the need for prompt recognition and treatment","volume":"4","author":"A S Carroll","year":"2023","journal-title":"J Anesthesiol Pain Ther"},{"key":"R8-20260729","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/AJP.0b013e318288e1f6","article-title":"The safety of liposome bupivacaine, a novel local analgesic formulation","volume":"30","author":"Viscusi","year":"2014","journal-title":"Clin J Pain"},{"key":"R9-20260729","first-page":"124","article-title":"Local anesthetic systemic toxicity: a review of recent case reports and registries","volume":"43","author":"Gitman","year":"2018","journal-title":"Reg Anesth Pain Med"},{"key":"R10-20260729","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/AAP.0000000000000544","article-title":"Incidence of local anesthetic systemic toxicity in orthopedic patients receiving peripheral nerve blocks","volume":"42","author":"M\u00f6rwald","year":"2017","journal-title":"Reg Anesth Pain Med"},{"key":"R11-20260729","first-page":"556","article-title":"Systemic toxicity and cardiotoxicity from local anesthetics: incidence and preventive measures","volume":"27","author":"Mulroy","year":"2002","journal-title":"Reg Anesth Pain Med"},{"key":"R12-20260729","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/01.aoa.0000512004.80967.ab","article-title":"Local anesthetic systemic toxicity: continuing professional development","volume":"37","author":"El-Boghdadly","year":"2017","journal-title":"Obstet Anesth Dig"},{"key":"R13-20260729","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/14740338.2018.1474200","article-title":"A comparison of approaches to identify possible cases of local anesthetic systemic toxicity in the FDA Adverse Event Reporting System (FAERS) database","volume":"17","author":"Dagenais","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"R14-20260729","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3810\/pgm.2014.01.2733","article-title":"A review of the compatibility of liposome bupivacaine with other drug products and commonly used implant materials","volume":"126","author":"Kharitonov","year":"2014","journal-title":"Postgrad Med"},{"key":"R15-20260729","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1097\/DSS.0000000000003559","article-title":"Efficacy of liposomal bupivacaine for pain control after large, complex Mohs resections: a matched cohort study","volume":"48","author":"Chang","year":"2022","journal-title":"Dermatol Surg"},{"key":"R16-20260729","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.burns.2020.06.011","article-title":"Intraoperative liposomal bupivacaine for skin graft donor site analgesia: a retrospective cohort study","volume":"47","author":"Artz","year":"2021","journal-title":"Burns"},{"key":"R17-20260729","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1213\/ANE.0000000000005115","article-title":"An observational study of the pharmacokinetics of surgeon-performed intercostal nerve blockade with liposomal bupivacaine for posterior-lateral thoracotomy analgesia","volume":"131","author":"Manson","year":"2020","journal-title":"Anesth Analg"},{"key":"R18-20260729","year":"2023"},{"key":"R19-20260729","doi-asserted-by":"crossref","first-page":"367","DOI":"10.5414\/CP201775","article-title":"Time to onset of analgesia following local infiltration of liposome bupivacaine in healthy volunteers: a randomized, single-blind, sequential cohort, crossover study","volume":"51","author":"Apseloff","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R20-20260729","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/ALN.0000000000004988","article-title":"Liposomal bupivacaine for peripheral nerve blockade: a randomized, controlled, crossover, triple-blinded pharmacodynamic study in volunteers","volume":"141","author":"Zadrazil","year":"2024","journal-title":"Anesthesiology"},{"key":"R21-20260729","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/jcph.6159","article-title":"A phase I study of the pharmacokinetics, pharmacodynamics, and safety of liposomal bupivacaine for sciatic nerve block in the popliteal fossa for bunionectomy","volume":"65","author":"Sessler","year":"2025","journal-title":"J Clin Pharmacol"},{"key":"R22-20260729","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/ALN.0000000000003630","article-title":"Clinical effectiveness of liposomal bupivacaine administered by infiltration or peripheral nerve block to treat postoperative pain: a narrative review","volume":"134","author":"Ilfeld","year":"2021","journal-title":"Anesthesiology"},{"key":"R23-20260729","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1213\/ANE.0000000000005406","article-title":"Comparison of liposomal bupivacaine and conventional local anesthetic agents in regional anesthesia: a systematic review","volume":"132","author":"Jin","year":"2021","journal-title":"Anesth Analg"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/DSS.0000000000005031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:02:05Z","timestamp":1785297725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/DSS.0000000000005031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000005031","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]}}}